I think the result is enough to get the shorts to think twice...

I think the result is enough to get the shorts to think twice here... the Macbank thesis has been the market is doomed and in a death spiral. As the market for TRT collapses, Axiron sales will fall and ACR is dead.
What we are seeing is not this case. Although market volumes for TRT and Axiron have come off - they have now flattend and Axiron is holding its position and sales in the market.

The international market is still showing promise and continues to grow - if the US market can hold a low growth scenario over the next couple of years combined with strong international growth, ACR may just hit the 50m milestone 2017?..... in the meantime patient shareholders (who have purchased in the low $1 range) can continue to collect some divs... something to think about.